C
TG Therapeutics, Inc.
TGTX
$37.15
-$0.20-0.54%
C
Hold
8/15/2024Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to C from C- on 8/15/2024 due to a major increase in the valuation index, efficiency index and total return index. Net income increased 164.25% from -$10.71M to $6.88M, and total capital increased 6.76% from $272.1M to $290.49M.
TG Therapeutics, Inc. (TGTX) was upgraded to C from C- on 8/15/2024 due to a major increase in the valuation index, efficiency index and total return index. Net income increased 164.25% from -$10.71M to $6.88M, and total capital increased 6.76% from $272.1M to $290.49M.
C
Hold
5/9/2024Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to C- from D on 5/9/2024 due to a significant increase in the growth index, efficiency index and valuation index. Total revenue increased 44.35% from $43.97M to $63.47M, operating cash flow increased 37.87% from -$13.21M to -$8.21M, and earnings per share increased from -$0.1007 to -$0.0732.
TG Therapeutics, Inc. (TGTX) was upgraded to C- from D on 5/9/2024 due to a significant increase in the growth index, efficiency index and valuation index. Total revenue increased 44.35% from $43.97M to $63.47M, operating cash flow increased 37.87% from -$13.21M to -$8.21M, and earnings per share increased from -$0.1007 to -$0.0732.
D
Sell
3/1/2024Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D from E+ on 3/1/2024 due to a significant increase in the efficiency index, solvency index and total return index. The quick ratio increased from 4.65 to 5.
TG Therapeutics, Inc. (TGTX) was upgraded to D from E+ on 3/1/2024 due to a significant increase in the efficiency index, solvency index and total return index. The quick ratio increased from 4.65 to 5.
E
Sell
3/14/2023Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D on 3/14/2023 due to a major decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.71 to 1.25, EBIT declined 48.91% from -$34.96M to -$52.06M, and earnings per share declined from -$0.2647 to -$0.3865.
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D on 3/14/2023 due to a major decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.71 to 1.25, EBIT declined 48.91% from -$34.96M to -$52.06M, and earnings per share declined from -$0.2647 to -$0.3865.
D
Sell
2/9/2023Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
TG Therapeutics, Inc. (TGTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from 0.55 to 0.71.
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from 0.55 to 0.71.
D
Sell
5/16/2022Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D from E+ on 05/16/2022.
TG Therapeutics, Inc. (TGTX) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D on 5/13/2022 due to a large decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.29 to 0.4, and the quick ratio declined from 4.84 to 4.28.
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D on 5/13/2022 due to a large decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.29 to 0.4, and the quick ratio declined from 4.84 to 4.28.
D
Sell
5/5/2022Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.06 to 0.29.
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.06 to 0.29.
D
Sell
11/10/2021Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 11/10/2021 due to an increase in the total return index.
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 11/10/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index.
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index.
D
Sell
8/13/2020Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to D from D+ on 8/13/2020 due to a decline in the valuation index.
TG Therapeutics, Inc. (TGTX) was downgraded to D from D+ on 8/13/2020 due to a decline in the valuation index.
D
Sell
6/17/2020Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D+ from D on 6/17/2020 due to an increase in the total return index, valuation index and volatility index.
TG Therapeutics, Inc. (TGTX) was upgraded to D+ from D on 6/17/2020 due to an increase in the total return index, valuation index and volatility index.
D
Sell
5/28/2020Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to D from D+ on 5/28/2020 due to a decline in the total return index and valuation index.
TG Therapeutics, Inc. (TGTX) was downgraded to D from D+ on 5/28/2020 due to a decline in the total return index and valuation index.
D
Sell
5/13/2020Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D+ from D on 5/13/2020 due to an increase in the valuation index and total return index.
TG Therapeutics, Inc. (TGTX) was upgraded to D+ from D on 5/13/2020 due to an increase in the valuation index and total return index.
D
Sell
5/1/2020Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 5/1/2020 due to a major increase in the total return index, solvency index and growth index. The quick ratio increased from 0.9 to 1.66, earnings per share increased from -$0.6907 to -$0.4133, and EBIT increased 37.63% from -$60.86M to -$37.96M.
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 5/1/2020 due to a major increase in the total return index, solvency index and growth index. The quick ratio increased from 0.9 to 1.66, earnings per share increased from -$0.6907 to -$0.4133, and EBIT increased 37.63% from -$60.86M to -$37.96M.
D
Sell
5/15/2019Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D- from E+ on 5/15/2019 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.6846 to -$0.4331, EBIT increased 35.94% from -$54.15M to -$34.69M, and operating cash flow increased 1.01% from -$33.69M to -$33.35M.
TG Therapeutics, Inc. (TGTX) was upgraded to D- from E+ on 5/15/2019 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.6846 to -$0.4331, EBIT increased 35.94% from -$54.15M to -$34.69M, and operating cash flow increased 1.01% from -$33.69M to -$33.35M.
E
Sell
3/4/2019Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D- on 3/4/2019 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 2.43 to 1.77.
TG Therapeutics, Inc. (TGTX) was downgraded to E+ from D- on 3/4/2019 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 2.43 to 1.77.
D
Sell
5/14/2018Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 5/14/2018 due to a decline in the growth index, total return index and efficiency index. Net income declined 34.57% from -$30.86M to -$41.53M, EBIT declined 33.97% from -$31.03M to -$41.58M, and operating cash flow declined 28.31% from -$21.86M to -$28.04M.
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 5/14/2018 due to a decline in the growth index, total return index and efficiency index. Net income declined 34.57% from -$30.86M to -$41.53M, EBIT declined 33.97% from -$31.03M to -$41.58M, and operating cash flow declined 28.31% from -$21.86M to -$28.04M.
D
Sell
3/16/2018Upgraded
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 3/16/2018 due to a noticeable increase in the total return index and efficiency index. Net income increased 2.14% from -$31.54M to -$30.86M.
TG Therapeutics, Inc. (TGTX) was upgraded to D from D- on 3/16/2018 due to a noticeable increase in the total return index and efficiency index. Net income increased 2.14% from -$31.54M to -$30.86M.
D
Sell
3/11/2016Downgrade
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index.
TG Therapeutics, Inc. (TGTX) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index.
NASDAQ
04/07/2025 10:11AM Eastern
Quotes delayed
